Tocqueville Asset Management L.P. Has $9.72 Million Stock Position in AxoGen, Inc. (NASDAQ:AXGN)

Tocqueville Asset Management L.P. decreased its position in AxoGen, Inc. (NASDAQ:AXGN) by 15.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 589,900 shares of the medical equipment provider’s stock after selling 105,000 shares during the period. Tocqueville Asset Management L.P. owned about 1.34% of AxoGen worth $9,722,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in AXGN. Principal Financial Group Inc. grew its stake in shares of AxoGen by 8.3% in the 4th quarter. Principal Financial Group Inc. now owns 16,000 shares of the medical equipment provider’s stock valued at $264,000 after purchasing an additional 1,228 shares during the period. Rhumbline Advisers grew its stake in shares of AxoGen by 2.7% in the 4th quarter. Rhumbline Advisers now owns 58,232 shares of the medical equipment provider’s stock valued at $960,000 after purchasing an additional 1,521 shares during the period. R Squared Ltd bought a new stake in shares of AxoGen in the 4th quarter valued at approximately $30,000. US Bancorp DE bought a new stake in shares of AxoGen in the 4th quarter valued at approximately $30,000. Finally, Quest Partners LLC grew its stake in shares of AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 2,076 shares during the period. Institutional investors and hedge funds own 80.29% of the company’s stock.

Analyst Upgrades and Downgrades

AXGN has been the topic of several analyst reports. Canaccord Genuity Group upped their price objective on AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. Lake Street Capital started coverage on AxoGen in a research report on Monday. They set a “buy” rating and a $30.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $24.00 price target on shares of AxoGen in a research report on Wednesday, March 5th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $22.60.

AxoGen Stock Up 6.0 %

NASDAQ AXGN opened at $18.28 on Tuesday. The firm has a market cap of $810.61 million, a PE ratio of -57.13 and a beta of 1.02. AxoGen, Inc. has a one year low of $5.55 and a one year high of $21.00. The stock’s 50 day simple moving average is $18.08 and its 200 day simple moving average is $15.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

Insider Buying and Selling at AxoGen

In other AxoGen news, Director Amy Mcbride Wendell sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total value of $100,100.00. Following the transaction, the director now directly owns 97,899 shares in the company, valued at approximately $1,959,937.98. This trade represents a 4.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.00% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.